Hesslein Robert W.
Known title: EVP, CLO and SecretaryCIK: 0001585018
Associated companies
Transaction History
| ALNY | ▲ Buy | Grant | 757 | $0 | 3/3/2025 | View on chart |
| ALNY | ▲ Buy | Grant | 7,245 | $0 | 10/1/2024 | View on chart |
| VYGR | ▼ Sell | Open Market | 4,410 | $34K | 3/20/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 3,297 | $25K | 2/17/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 2,868 | $22K | 2/13/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 1,396 | $13K | 1/17/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 792 | $8K | 1/17/2023 | View on chart |
| VYGR | ▼ Sell | Open Market | 2,786 | $23K | 4/4/2022 | View on chart |
| VYGR | ▼ Sell | Open Market | 4,897 | $41K | 3/21/2022 | View on chart |
| VYGR | ▼ Sell | Open Market | 58 | $503 | 3/21/2022 | View on chart |
| VYGR | ▼ Sell | Open Market | 4,100 | $15K | 2/17/2022 | View on chart |
| VYGR | ▼ Sell | Open Market | 3,252 | $11K | 2/11/2022 | View on chart |
| VYGR | ▲ Buy | Grant | 20,000 | $0 | 1/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets
Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.